Incyte licensed worldwide rights to develop and commercialize MGA012, MacroGenics' anti-PD-1 monoclonal antibody, in all indications. MacroGenics received $150M upfront plus eligibility for up to $420M in development/regulatory milestones and up to $330M in commercial milestones (~$900M total) plus tiered 15-24% royalties on net sales. MacroGenics retained rights to use MGA012 in combination with its proprietary pipeline.
Did it work? Outcome assessment
Strategic verdict
Partially Achieved
Financial impact
Dilutive
Pipeline outcome
Mixed
Assessment window: 5yr post-close.
Key facts
AnnouncedOct 25, 2017
ClosedDec 05, 2017
Deal value$900M
Deal typeLicensing/Option
Therapeutic areaMultiple solid tumors and hematologic malignancies
IndicationsMultiple solid tumors and hematologic malignancies